Coherus Oncology (NASDAQ: CHRS) revenue
Coherus Oncology reported revenue of $42.2m for fiscal 2025, 59.8% more than in fiscal 2024 ($26.4m). Since fiscal 2016 its revenue has fallen by 77.8%, an average decline of 15.4% a year.
Coherus Oncology's best year of the last 10 was fiscal 2020. The biggest drop was in fiscal 2017, −99.2%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $42.2m | +59.8% | −$181.1m | −429.5% |
| 2024 | $26.4m | −89.7% | −$199.7m | −756.6% |
| 2023 | $257.2m | +21.9% | −$203.2m | −79.0% |
| 2022 | $211.0m | −35.4% | −$256.9m | −121.7% |
| 2021 | $326.6m | −31.4% | −$263.9m | −80.8% |
| 2020 | $475.8m | +33.6% | $156.3m | 32.9% |
| 2019 | $356.1m | — | $107.8m | 30.3% |
| 2018 | $0.0m | −100.0% | −$204.4m | — |
| 2017 | $1.6m | −99.2% | −$232.1m | −14,918.8% |
| 2016 | $190.1m | — | −$115.9m | −61.0% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Coherus Oncology revenue compared with its sector
By revenue for its latest fiscal year, Coherus Oncology ranks 335th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Coherus Oncology, 59.8%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 333rd | Aquestive Therapeutics | $44.5m | −22.6% |
| 334th | Wave Life Sciences | $42.7m | −60.5% |
| 335th | Coherus Oncology | $42.2m | 59.8% |
| 336th | Koru Medical Systems | $41.1m | 22.2% |
| 337th | Editas Medicine | $40.5m | 25.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Coherus Oncology
- How much revenue did Coherus Oncology make in fiscal 2025?
- Coherus Oncology reported revenue of $42.2m for fiscal 2025, compared with $26.4m in fiscal 2024.
- How much has the revenue of Coherus Oncology fallen?
- Between fiscal 2016 and fiscal 2025 it went from $190.1m to $42.2m: 77.8% less, an average decline of 15.4% a year.
- What was the best year for revenue at Coherus Oncology?
- Of its last 10 fiscal years, fiscal 2020, with $475.8m.
- Where does Coherus Oncology rank in its sector by revenue?
- It ranks 335th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Coherus Oncology come from?
- From the annual report (Form 10-K) that Coherus Oncology files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Coherus Oncology files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Coherus Oncology: the Coherus Oncology page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.